MUMBAI (Reuters) - Shares in Sun Pharmaceutical Industries slumped as much as 16.11 percent, heading towards their biggest daily fall ever, after the drugmaker on Monday said it sees 2016 sales flat at best.
Analysts say results warning can cut FY16 consensus earnings estimates by 8-10 percent as company struggles to fix manufacturing problems at Ranbaxy Laboratories , which it bought last year.
(Reporting by Abhishek Vishnoi; Editing by Gopakumar Warrier)